GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 14 Mar 2013.
Apolipoprotein A-II
Apolipoprotein A-II, apoA-II
This gene encodes apolipoprotein (apo-) A-II, which is the second most abundant protein of the high density lipoprotein particles. The protein is found in plasma as a monomer, homodimer, or heterodimer with apolipoprotein D. Defects in this gene may result in apolipoprotein A-II deficiency or hypercholesterolemia. [provided by RefSeq, Jul 2008] (from
NCBI)
Sponsored links
Papers on
Apolipoprotein A-II
Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat.
New
Oklahoma City, United States. In J Clin Lipidol, 31 Mar 2013
During treatment, the children were observed to have elevations in apolipoprotein (apo)B, low-density lipoprotein particle concentration, abnormal apoB-containing subclasses, and deficiencies in apoA-I and apoA-II-containing lipoproteins, changes consistent with continuing increased cardiovascular risk.
Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.
New
Japan. In Arterioscler Thromb Vasc Biol, 28 Feb 2013
OBJECTIVE: Apolipoprotein (apo) A-II is the second major apo of high-density lipoproteins, yet its pathophysiological roles in the development of atherosclerosis remain unknown.
SAA does not induce cytokine production in physiological conditions.
New
Lexington, United States. In Cytokine, 28 Feb 2013
Stimulation of mouse monocyte J774 cells with lipid-poor recombinant human SAA and purified SAA derived from cardiac surgery patients, but not ApoA-I and ApoA-II, elicited pro-inflammatory cytokines like granulocyte colony stimulating factor (G-CSF).
Structural basis of specific interactions of Lp-PLA2 with HDL revealed by hydrogen deuterium exchange mass spectrometry.
New
San Diego, United States. In J Lipid Res, Jan 2013
We now find that residues 192-204 show a decreased deuteration level when Lp-PLA(2) is exposed to apoA-I, but not apoA-II, the most abundant apoproteins in HDL, and additionally, residues 360-368 are only affected by HDL.The results suggest that apoA-I and phospholipid membranes play crucial roles in Lp-PLA(2) localization to HDL.
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
New
Sydney, Australia. In J Clin Endocrinol Metab, Dec 2012
The effect of fenofibrate treatment on serum FGF21, but not RBP4, remained significant after adjusting for fenofibrate-induced changes in glycosylated hemoglobin, total cholesterol, triglycerides, apolipoprotein A-II, fibrinogen, plasma creatinine, and homocysteine (P = 0.002).
Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.
Review
New
Perth, Australia. In Ann Med, Jun 2012
ApoA-II, a constituent apolipoprotein of certain HDL particles, plays an important role in the regulation of cholesterol efflux, HDL remodelling, and cholesteryl ester uptake via its interactions with lipid transfer proteins, lipases, and cellular HDL receptors.
ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis.
GeneRIF
Matsumoto, Japan. In J Lipid Res, 2011
ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis.
Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction.
GeneRIF
Boston, United States. In Int J Obes (lond), 2011
a gene-diet interaction involving the APOA2 -265T>C SNP and saturated fat intake determines body weight in a Mediterranean and an Asian populations
Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function.
GeneRIF
Chiba, Japan. In J Immunol, 2011
Exacerbated hepatitis is observed in ApoA-II-deficient mice, indicating that ApoA-II plays a suppressive role in concanavalin A-induced hepatitis under physiological conditions.
Apolipoproteins and amyloid fibril formation in atherosclerosis.
Review
Melbourne, Australia. In Protein Cell, 2011
A number of plasma apolipoproteins, including apolipoprotein (apo) A-I, apoA-II, apoC-II and apoE are implicated in amyloid formation or influence amyloid formation by other proteins.
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
GeneRIF
Utrecht, Netherlands. In Ann Oncol, 2010
Low apolipoprotein-A2 is associated with metastatic renal cell cancer.
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
Review
Philadelphia, United States. In Atherosclerosis, 2010
Fibrates also increase HDL apoA-I and apoA-II levels by enhancing apoA-I and apoA-II production, although this is partially counteracted by increasing fractional catabolism of these apolipoproteins.
Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
GeneRIF
Barcelona, Spain. In Arterioscler Thromb Vasc Biol, 2010
ApoA-II plays a crucial role in triglyceride catabolism by regulating lipoprotein lipase activity, at least in part, through HDL proteome modulation.
HDL metabolism in context: looking on the bright side.
Review
Perth, Australia. In Curr Opin Lipidol, 2008
RESULTS: HDL-apoA-I and apoA-II may be better predictors of cardiovascular disease than HDL-cholesterol.
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
Review
Birmingham, United States. In J Lipid Res, 2007
Another protein component of HDL, apoA-II, has structural features similar to those of apoA-I but does not possess atheroprotective properties.
High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase.
Impact
Dallas, United States. In Nat Med, 2001
In contrast, eNOS is not activated by purified forms of the major HDL apolipoproteins ApoA-I and ApoA-II or by low-density lipoprotein.
Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23.
Impact
Helsinki, Finland. In Nat Genet, 1998
One marker, D1S104, adjacent to the apolipoprotein A-II (APOA2) gene on chromosome 1, revealed a lod score of Z = 3.50 assuming a dominant mode of inheritance.
Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
Impact
Berkeley, United States. In Nature, 1993
High-density lipoprotein (HDL) contains two major proteins, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), comprising about 70% and 20% of the total HDL protein mass, respectively.
Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
Impact
Los Angeles, United States. In Science, 1993
The two most abundant protein constituents of HDL are apolipoproteins A-I and A-II (apoA-I and apoA-II).
A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.
Impact
In Jama, 1988
Cholestyramine resin treatment had no significant effect on very low-density lipoprotein cholesterol and apolipoprotein A-II levels and produced a median 11% increase in plasma triglyceride concentration; in contrast, administration of either 20 or 40 mg of lovastatin twice a day was associated with median reductions in very low-density lipoprotein cholesterol levels (-34% and -31%, respectively) and plasma triglyceride levels (-21% and -27%, respectively) and median increases in levels of apolipoprotein A-II (8% and 13%, respectively).
